Full Text View
Tabular View
No Study Results Posted
Related Studies
Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
This study has been terminated.
Study NCT00113048   Information provided by Genzyme

First Received on June 3, 2005.   Last Updated on July 28, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hematologic Malignancies
Additional conditions recognized in this trial
Hematologic Neoplasms
Neoplasms
More general conditions related to this trial
Hematologic Diseases
Neoplasms by Site
Interventions listed in this trial
CAMPATH (alemtuzumab)
Additional drug interventions recognized in this trial
Alemtuzumab
Campath 1G
More general drug interventions related to this trial
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Genzyme


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services